A high proportion of patients may fail a first-line anti-TNF drug, necessitating the switch to another anti-TNF treatment. After 12 months of GLM treatment, 80% of RA patients achieved low disease activity (LDA), 37.1% with PsA achieved minimal disease activity and 55.3% with axSpA achieved LDA while persistence at 12 months in all patients was 77.7%. In this 1-year analysis of the GO-BEYOND study in Italy, GLM had a favorable benefit: risk profile and high retention rate in patients with PsA, RA and axSpA.
Real-world effectiveness and persistence of golimumab as second-line anti-TNFα drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO-BEYOND, a 12-month prospective observational study / D'Angelo, S; Tirri, E; Giardino, Am; De Rosa, T; Matucci-Cerinic, M; Dagna, L; Santo, L; Ciccia, F; Frediani, B; Govoni, M; Pallavicini, Fb; Grembiale, Rd; Sedie, Ad; Mulè, R; Cantatore, Fp; Foti, R; Gremese, E; Conigliaro, P; Salaffi, F; Viapiana, O; Cauli, A; Giacomelli, R; Arcarese, L; Guggino, G; Russo, R; Puenpatom, A; Capocotta, D; Nacci, F; Anelli, Mg; Picerno, V; Binetti, C; Iannone, F; GO-BEYOND Italy Study, Investigators.. - In: INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES. - ISSN 1756-185X. - STAMPA. - 27:3(2024), pp. 1-7. [10.1111/1756-185X.15091]
Real-world effectiveness and persistence of golimumab as second-line anti-TNFα drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO-BEYOND, a 12-month prospective observational study
De Rosa T;Salaffi F;Russo R;
2024-01-01
Abstract
A high proportion of patients may fail a first-line anti-TNF drug, necessitating the switch to another anti-TNF treatment. After 12 months of GLM treatment, 80% of RA patients achieved low disease activity (LDA), 37.1% with PsA achieved minimal disease activity and 55.3% with axSpA achieved LDA while persistence at 12 months in all patients was 77.7%. In this 1-year analysis of the GO-BEYOND study in Italy, GLM had a favorable benefit: risk profile and high retention rate in patients with PsA, RA and axSpA.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
